Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México; Departamento de Hematología, Unidad Médica de Alta Especialidad, Hospital Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México; Unidad de Investigación de Medicina Traslacional en Enfermedades Hemato-Oncologicas, Unidad Médica de Alta Especialidad, Hospital Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México.
Arch Med Res. 2020 Apr;51(3):194-203. doi: 10.1016/j.arcmed.2020.01.013. Epub 2020 Feb 26.
Tumor immunoedition involves alterations in cells of immune system, which may play an important role in the immunosurveillance of patients with cancer diseases.
To determine the association between the number of immune cells and the expression of surface markers in leukemic cells of patients with de novo CML who achieved molecular response.
A longitudinal study was conducted in 31 patients with de novo CML. Peripheral blood samples were obtained at diagnosis for quantification of immune cells and tumor cells expressing CD200, CD135, GpP, and Bcl-2. Results were compared with a group of 60 healthy donors. Lymphocyte subsets were analyzed during a 48 month follow-up period and molecular response to treatment was assessed simultaneously by QT-PCR. The group of patients with deep molecular response was compared with de novo CML patients; the cut-off value of cell count was determined by ROC analysis. Kaplan-Meier and Cox proportional hazard model were used to determine the significant association between the number of cells and progression-free survival.
Differences in number of CD4, CD4Tregs, NK, γδT, monocytes, and pDC's, tumor-cells expressing CD200, CD135, GpP, and Bcl-2 were observed between patients and healthy donors. The number of γδT lymphocytes, CD200, and CD135 cells were associated with longer progression-free survival (p = 0.0112, p = 0.0012 and p = 0.0201 respectively).
A γδT lymphocyte count <63 cel/uL, CD200 <997 cel/uL, and CD135 <23 317 cel/uL at diagnosis is associated with the maintenance of deep molecular response at 48 months in patients with de novo CML.
肿瘤免疫编辑涉及免疫系统细胞的改变，这可能在癌症患者的免疫监视中发挥重要作用。
确定新诊断的 CML 患者达到分子缓解时免疫细胞数量与白血病细胞表面标志物表达之间的关系。
对 31 例新诊断的 CML 患者进行了一项纵向研究。在诊断时获得外周血样本，以定量检测表达 CD200、CD135、GpP 和 Bcl-2 的免疫细胞和肿瘤细胞。将结果与 60 名健康供体进行比较。在 48 个月的随访期间分析淋巴细胞亚群，并同时通过 QT-PCR 评估治疗的分子反应。将深度分子反应组与新诊断的 CML 患者进行比较；通过 ROC 分析确定细胞计数的临界值。使用 Kaplan-Meier 和 Cox 比例风险模型确定细胞数量与无进展生存期之间的显著相关性。
患者与健康供体之间观察到 CD4、CD4Tregs、NK、γδT、单核细胞和 pDC 的数量、表达 CD200、CD135、GpP 和 Bcl-2 的肿瘤细胞存在差异。γδT 淋巴细胞、CD200 和 CD135 细胞的数量与无进展生存期延长相关（p=0.0112、p=0.0012 和 p=0.0201）。
新诊断的 CML 患者在诊断时γδT 淋巴细胞计数<63 cel/uL、CD200<997 cel/uL 和 CD135<23 317 cel/uL 与 48 个月时深度分子缓解的维持相关。
